Search

The first case of disseminated Mycobacterium bovis infection with meningitis in an AIDS patient is reported. A 54-year-old male HIV-positive patient was admitted for evaluation of fever, weight loss, inappetence, fatigue and malaise. Mycobacterium bovis (non-BCG) was isolated from blood, bone marrow, stool, urine, sputum, abdominal lymph nodes and cerebrospinal fluid. Antituberculous therapy using a five-drug regimen plus steroids resulted in complete recovery.

Central nervous system disease due to Toxoplasma gondii is a common cause of morbidity and mortality in patients with the acquired immunodeficiency syndrome. Cardiac toxoplasmosis, however, has been described in only a limited number of cases. In a 45-year-old patient with symptoms suggestive of myocarditis, Toxoplasma gondii was detected in myocardial tissue obtained by biopsy. After the institution of appropriate antiprotozoal therapy, the patient recovered. This patient is believed to be the first patient to survive biopsy-proven myocarditis caused by Toxoplasma gondii. Cardiac toxoplasmosis should be ruled out in HIV-infected patients presenting with high fever and/or cardiorespiratory symptoms and exhibiting serologic evidence of prior exposure to Toxoplasma gondii as determined by a positive IgG EIA, especially if the CD4+ count is low and no systemic Pneumocystis carinii pneumonia prophylaxis has been administered. A high index of clinical suspicion and, if necessary, invasive diagnostic tests, including myocardial biopsies, are most important in making the correct diagnosis.

Twenty-eight patients with different stages of HIV infection who had not undergone antiretroviral pretreatment were treated with an escalating dose regimen of zidovudine (4 weeks 2 x 50 mg, 4 weeks 2 x 100 mg, 4 weeks 2 x 250 mg). CD4+ cell counts and p24 antigen levels were monitored every four weeks. Twenty-one patients were evaluable. p24 antigen levels showed a significant decrease after four weeks (p < 0.01, Sign test, Wilcoxon matched pairs test) that was sustained until week 12 without a further significant decrease. CD4+ cell counts increased significantly within the first four weeks (p < 0.01, Sign test, Wilcoxon matched pairs test). This increase was sustained until week 12 but no further significant increase was noted. Mean corpuscular erythrocyte volume values increased significantly after week 4 and continued to rise until week 12. These results demonstrate antiretroviral activity of a very low zidovudine dose, however low doses should not be used for treatment unless the clinical efficacy is shown to be equivalent to that of standard doses.